MX359626B - Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction. - Google Patents

Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction.

Info

Publication number
MX359626B
MX359626B MX2015013275A MX2015013275A MX359626B MX 359626 B MX359626 B MX 359626B MX 2015013275 A MX2015013275 A MX 2015013275A MX 2015013275 A MX2015013275 A MX 2015013275A MX 359626 B MX359626 B MX 359626B
Authority
MX
Mexico
Prior art keywords
selenium
same
compositions
disease
prevention
Prior art date
Application number
MX2015013275A
Other languages
Spanish (es)
Other versions
MX2015013275A (en
Inventor
Kwiatkowski Stefan
Power Ronan
Egan Casey
Yiannikouris Alexander
Lan Zi-Jian
Xiao Rijin
Collen Jackson Lewis
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of MX2015013275A publication Critical patent/MX2015013275A/en
Publication of MX359626B publication Critical patent/MX359626B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present application relates to compositions comprising selenium (e.g., selenium enriched yeast and selenium containing compounds obtained or derived therefrom) and methods of using the same to treat and inhibit obesity, diabetes and related conditions. In particular, the present application provides compositions comprising selenium enriched yeast (e.g., selenium enriched yeast comprising 2% or less inorganic selenium), selenium containing compounds present therein and/or derived therefrom, and methods of using the same to enhance mitochondrial activity and function (e.g., in skeletal muscle and liver) in a subject (e.g., as a therapeutic and/or prophylactic treatment for diabetes, obesity and related conditions).
MX2015013275A 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction. MX359626B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Publications (2)

Publication Number Publication Date
MX2015013275A MX2015013275A (en) 2015-12-11
MX359626B true MX359626B (en) 2018-10-01

Family

ID=51537786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013275A MX359626B (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction.

Country Status (15)

Country Link
US (1) US9833486B2 (en)
EP (1) EP2968404A4 (en)
JP (1) JP6313418B2 (en)
KR (1) KR102245702B1 (en)
CN (3) CN114533753A (en)
AU (1) AU2014228785B2 (en)
BR (1) BR112015022514A2 (en)
CA (1) CA2903845C (en)
CL (1) CL2015002677A1 (en)
HK (1) HK1216506A1 (en)
MX (1) MX359626B (en)
RU (1) RU2663127C2 (en)
SG (2) SG10202101918RA (en)
WO (1) WO2014144776A1 (en)
ZA (1) ZA201506759B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513712A (en) 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， Cholestosome vesicles for uptake of molecules into chylomicrons
CN106456658A (en) * 2014-03-14 2017-02-22 全技术公司 Compositions of selenoorganic compounds and methods of use thereof
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
JP2019508507A (en) * 2016-03-14 2019-03-28 マイトジェネティクス リミテッド ライアビリティ カンパニー Materials and methods for treating hypoxic conditions
JP7224303B2 (en) 2017-05-19 2023-02-17 オールテック，インク． Agents, compositions, and related methods
CN108283711A (en) * 2018-05-06 2018-07-17 冷立娟 A kind of instant particles as Chinese medicine and preparation method thereof for treating alcoholic myocardiopathy
CN109820933A (en) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 Weight-reducing tablet and preparation method thereof
CN111493325A (en) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 Application of plant selenium peptide in preparation of composition for improving obesity and metabolic syndrome
CN112129864B (en) * 2020-09-24 2022-04-01 江南大学 Method for determining selenium form in selenium-rich plant dry powder
KR102328808B1 (en) * 2020-12-02 2021-11-22 동의대학교 산학협력단 Composition for preventing and improving sarcopenia using brewer's yeast
CN114053298A (en) * 2021-11-19 2022-02-18 华中农业大学 Medicine for inhibiting myocardial hypertrophy and construction method of model
CN114235989A (en) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 High performance liquid chromatography for determining content of asomate
CN114031650B (en) * 2021-11-29 2023-05-02 上海交通大学 Chitosan oligosaccharide selenium coordination compound and preparation method and application thereof
CN114931569B (en) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 Application of methylselenocysteine in preparation of product for improving male reproductive capacity
CN116333302A (en) * 2023-03-31 2023-06-27 中南大学 Stable and durable antioxidant nano-dot and application thereof in type II diabetes
CN116421618B (en) * 2023-06-15 2023-09-29 暨南大学 Preparation method of Se@NADH and application of Se@NADH in spinal cord injury treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (en) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル Platinum toxicity detoxicant
OA13177A (en) * 2003-06-04 2006-12-13 Willem Jacob Serfontein Nutritional compositions and use thereof.
PL214402B1 (en) * 2003-08-11 2013-07-31 Tomasz Byrski Pharmaceutical compound, application of selenium or its compounds as well as the method for reducing breast or ovary cancer hazard
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
TWI319708B (en) * 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
US8846111B2 (en) * 2007-05-18 2014-09-30 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin Method for the selective therapy of disease
CN102056499B (en) * 2007-10-16 2014-12-31 阿克特基因组学有限公司 Composition for regulating lipid metabolism
CN101579355B (en) * 2009-05-27 2010-12-08 徐建兴 Nutrition composition used for maintaining functions of mitochondria and application thereof
SG10201406651PA (en) * 2009-10-22 2014-11-27 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
WO2011132799A1 (en) * 2010-04-22 2011-10-27 Kyoto University Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells
KR20120048205A (en) * 2010-11-05 2012-05-15 한국식품연구원 Composition for prevention and treatment of obesity and metabolic diseases comprising methylselenocysteine
KR102100091B1 (en) 2011-04-13 2020-04-14 아지노모토 가부시키가이샤 Nutritional composition

Also Published As

Publication number Publication date
AU2014228785A1 (en) 2015-09-24
BR112015022514A2 (en) 2017-07-18
US9833486B2 (en) 2017-12-05
RU2015139742A (en) 2017-04-21
WO2014144776A1 (en) 2014-09-18
CL2015002677A1 (en) 2016-12-09
HK1216506A1 (en) 2016-11-18
EP2968404A4 (en) 2017-01-04
CN114984038A (en) 2022-09-02
JP6313418B2 (en) 2018-04-18
CA2903845C (en) 2022-08-23
SG10202101918RA (en) 2021-03-30
RU2663127C2 (en) 2018-08-01
JP2016516058A (en) 2016-06-02
KR102245702B1 (en) 2021-04-28
SG11201507061XA (en) 2015-10-29
EP2968404A1 (en) 2016-01-20
AU2014228785B2 (en) 2018-01-25
ZA201506759B (en) 2017-03-29
MX2015013275A (en) 2015-12-11
CN114533753A (en) 2022-05-27
NZ711842A (en) 2021-04-30
CA2903845A1 (en) 2014-09-18
US20160113977A1 (en) 2016-04-28
KR20150132374A (en) 2015-11-25
CN105377271A (en) 2016-03-02

Similar Documents

Publication Publication Date Title
MX359626B (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction.
MX2018007022A (en) Methods for treatng huntington's disease.
MX2019014514A (en) Compounds for treating huntington's disease.
MX2017016424A (en) Compounds for use in treating neuromuscular disorders.
MX345535B (en) Partially saturated tricyclic compounds and methods of making and using same.
EA201890641A2 (en) STIMULATORS sGC
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2016003582A (en) Compound inhibiting kinase activities of btk and/or jak3.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX343687B (en) Tricyclic sulfonamide compounds and methods of making and using same.
MX344238B (en) Tetrazole compounds and methods of making and using same.
BR112015024846A2 (en) compositions for use in stimulating bone growth
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
MX2017011182A (en) Amylin analogues.
MX2014008706A (en) Tricyclic sulfonamide compounds and methods of making and using same.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX365366B (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne.
MX355330B (en) CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF.
MX366368B (en) Prebiotic oral care methods using a saccharide.
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
MX2015008877A (en) Mixed disulfide conjugates of thienopyridine compounds and uses thereof.
WO2012135528A3 (en) Galectin-3c combination therapy for human cancer
MX342119B (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
MX2014012742A (en) Composition for treating metabolic disorders.

Legal Events

Date Code Title Description
FG Grant or registration